MSD SUB MERCK Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD SUB MERCK, and when can generic versions of MSD SUB MERCK drugs launch?
MSD SUB MERCK has fourteen approved drugs.
There are twenty US patents protecting MSD SUB MERCK drugs.
There are five hundred and forty-nine patent family members on MSD SUB MERCK drugs in sixty countries and one hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for MSD SUB MERCK
International Patents: | 549 |
US Patents: | 20 |
Tradenames: | 13 |
Ingredients: | 11 |
NDAs: | 14 |
Drugs and US Patents for MSD SUB MERCK
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET;ORAL | 022145-001 | Oct 12, 2007 | RX | Yes | Yes | 7,754,731*PED | ⤷ Free Trial | Y | ⤷ Free Trial | |||
Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET;ORAL | 022145-001 | Oct 12, 2007 | RX | Yes | Yes | 7,169,780*PED | ⤷ Free Trial | ⤷ Free Trial | ||||
Msd Sub Merck | STEGLATRO | ertugliflozin | TABLET;ORAL | 209803-001 | Dec 19, 2017 | AB | RX | Yes | No | 8,080,580 | ⤷ Free Trial | Y | Y | ⤷ Free Trial | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MSD SUB MERCK
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | JANUMET XR | metformin hydrochloride; sitagliptin phosphate | TABLET, EXTENDED RELEASE;ORAL | 202270-002 | Feb 2, 2012 | 6,890,898 | ⤷ Free Trial |
Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | 5,478,820*PED | ⤷ Free Trial |
Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | 7,265,009 | ⤷ Free Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2008-09-30 |
➤ Subscribe | Injection | 0.75 mg/mL, 100 mL vial | ➤ Subscribe | 2009-06-05 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2011-10-12 |
➤ Subscribe | Extended-release Capsules | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2012-03-16 |
➤ Subscribe | Tablets | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2010-10-18 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL vial | ➤ Subscribe | 2008-12-18 |
➤ Subscribe | Injection | 1 g/vial | ➤ Subscribe | 2013-06-20 |
➤ Subscribe | Ophthalmic Solution | 2% | ➤ Subscribe | 2005-10-11 |
➤ Subscribe | Extended-release Tablets | 100 mg/1000 mg | ➤ Subscribe | 2012-10-22 |
International Patents for MSD SUB MERCK Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 62600 | ⤷ Free Trial |
Austria | E540040 | ⤷ Free Trial |
Lithuania | PA2016049 | ⤷ Free Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for MSD SUB MERCK Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1506211 | 122014000071 | Germany | ⤷ Free Trial | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
1506211 | 92496 | Luxembourg | ⤷ Free Trial | PRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1 |
1506211 | CR 2014 00037 | Denmark | ⤷ Free Trial | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.